ACLX | Arcellx, Inc.

Index	-	P/E	-	EPS (ttm)	-4.29	Insider Own	15.44%	Shs Outstand	46.77M	Perf Week	-1.94%
Market Cap	2.13B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-22.14%	Shs Float	39.95M	Perf Month	-3.43%
Income	-190.00M	PEG	-	EPS next Q	-0.28	Inst Own	96.00%	Short Float / Ratio	15.19% / 11.66	Perf Quarter	48.80%
Sales	17.90M	P/S	118.84	EPS this Y	-177.80%	Inst Trans	16.21%	Short Interest	6.07M	Perf Half Y	110.58%
Book/sh	6.49	P/B	6.47	EPS next Y	-29.70%	ROA	-46.10%	Target Price	51.40	Perf Year	243.62%
Cash/sh	10.53	P/C	3.99	EPS next 5Y	-	ROE	-71.10%	52W Range	11.95 - 48.92	Perf YTD	35.54%
Dividend	-	P/FCF	18.91	EPS past 5Y	-	ROI	-	52W High	-14.16%	Beta	-
Dividend %	-	Quick Ratio	3.40	Sales past 5Y	-	Gross Margin	-	52W Low	251.23%	ATR	2.48
Employees	98	Current Ratio	3.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.27	Volatility	6.24% 5.89%
Optionable	Yes	Debt/Eq	0.17	EPS Q/Q	19.80%	Profit Margin	-	Rel Volume	1.42	Prev Close	44.32
Shortable	Yes	LT Debt/Eq	0.05	Earnings	Mar 29 AMC	Payout	-	Avg Volume	520.53K	Price	41.99
Recom	1.40	SMA20	-2.81%	SMA50	11.65%	SMA200	50.37%	Volume	740,349	Change	-5.26%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 06:11AM	Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts (Simply Wall St.)
May-08-23 05:15PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides First Quarter Financial Results (PR Newswire)
May-04-23 04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
06:44AM	Loading…
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
Apr-28-23 03:34PM	Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript (Motley Fool)
Apr-25-23 12:00PM	Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy? (Zacks)
Apr-21-23 12:00PM	Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.50%
Apr-13-23 04:01PM	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire)
Apr-11-23 10:00AM	Best Momentum Stocks to Buy for April 11th (Zacks)
Apr-05-23 09:55AM	Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know (Zacks)
Apr-04-23 12:20PM	Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? (Zacks)
Apr-03-23 08:34AM	Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't? (Zacks)
Mar-29-23 05:25PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (PR Newswire)
Mar-16-23 12:18PM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Feb-21-23 04:00PM	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire) -5.09%
Feb-02-23 04:00PM	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)
Jan-30-23 09:00AM	Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
Jan-04-23 11:45AM	Gilead's (GILD) Application for Trodelvy Gets EMA Validation (Zacks)
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-12-22 10:55AM	Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology (Zacks)
Dec-09-22 04:08PM	Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences (Investor's Business Daily) +29.24%
09:54AM	Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead (Barrons.com)
09:42AM	Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate (Benzinga)
08:46AM	Gilead to co-develop Arcellx's multiple myeloma drug (MarketWatch)
08:17AM	Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
08:17AM	Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress (PR Newswire)
08:15AM	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
11:08AM	Loading…
Nov-30-22 11:08AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-14-22 04:00PM	Arcellx Reports Third Quarter 2022 Financial Results and Business Progress (PR Newswire)
01:13PM	The bear market rally has more room to run, Guggenheim says. Here are 2 stocks to bet on (TipRanks)
Oct-27-22 02:37PM	Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock (Benzinga)
Sep-08-22 09:55AM	Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet (Zacks)
Aug-15-22 04:00PM	Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results (PR Newswire)
Aug-01-22 08:00AM	Gaithersburg biotech inks deal for Rockville expansion as two more office buildings are converted to lab space (American City Business Journals) +6.32%
Jun-23-22 10:50AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.) +7.89%
Jun-21-22 04:05PM	Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel (PR Newswire)
04:01PM	Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares (PR Newswire)
Jun-15-22 10:47PM	Arcellx Announces Upsizing and Pricing of Follow-On Public Offering (PR Newswire)
Jun-10-22 05:00PM	ASCO 2022: Surprising News in Cancer Research (Motley Fool) +16.39%
Jun-06-22 04:09PM	How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer (Investor's Business Daily) +20.63%
Jun-03-22 04:00PM	Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting (PR Newswire)
May-27-22 09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting (MarketWatch) +20.56%
May-23-22 04:05PM	Arcellx Appoints Michelle Gilson as Chief Financial Officer (PR Newswire) +11.03%
May-16-22 04:01PM	Arcellx Appoints Olivia Ware to Board of Directors (PR Newswire) -14.59%
May-12-22 04:01PM	Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results (PR Newswire)
May-10-22 04:01PM	Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire) +13.60%
May-09-22 04:01PM	Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire) -7.28%
10:00AM	Here's What Arcellx, Inc.'s (NASDAQ:ACLX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
May-05-22 04:01PM	Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference (PR Newswire)
Apr-27-22 10:00AM	Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-08-22 01:00PM	Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting (PR Newswire)
Mar-24-22 04:01PM	Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results (PR Newswire)
Mar-10-22 04:26PM	Arcellx Announces Participation at the Barclays Global Healthcare Conference (PR Newswire)
Mar-08-22 05:25PM	Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 (PR Newswire)
Feb-08-22 04:01PM	Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
01:54PM	5 things to know about this cancer-focused biopharmas recent IPO (American City Business Journals)
Feb-04-22 05:03PM	Arcellx and Nuvectis Pharma Begin Trading. Heres how They Did. (Barrons.com)
02:49PM	CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19 (Benzinga)
01:57AM	Arcellx Announces Pricing of Initial Public Offering (GlobeNewswire)

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carroll Jill	Director	Jun 01	Sale	44.35	25,556	1,133,317	2,487,674	Jun 02 04:56 PM
Carroll Jill	Director	May 31	Sale	41.50	315,164	13,079,306	2,513,230	Jun 02 04:56 PM
Elghandour Rami	See Remarks	May 31	Sale	44.27	2,600	115,099	36,169	Jun 02 05:10 PM
Gilson Michelle	Chief Financial Officer	May 25	Sale	42.77	6,000	256,616	9,485	May 25 08:21 PM
Gilson Michelle	Chief Financial Officer	May 24	Sale	42.46	8,704	369,534	15,485	May 25 08:21 PM
Gilson Michelle	Chief Financial Officer	May 23	Option Exercise	0.00	22,428	0	24,189	May 25 08:21 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11	Sale	45.01	1,012,833	45,589,317	1,658,780	May 15 06:16 PM
Carroll Jill	Director	May 11	Sale	45.01	638,417	28,736,223	2,828,394	May 15 06:18 PM
Heery Christopher	Chief Medical Officer	May 10	Sale	45.18	2,197	99,266	7,795	May 11 04:10 PM
Heery Christopher	Chief Medical Officer	May 09	Sale	45.00	500	22,500	9,992	May 11 04:10 PM
Heery Christopher	Chief Medical Officer	May 05	Sale	45.00	1,200	54,002	10,492	May 08 06:50 PM
Heery Christopher	Chief Medical Officer	May 03	Option Exercise	15.00	3,000	45,000	14,692	May 05 04:10 PM
Heery Christopher	Chief Medical Officer	May 03	Sale	43.44	3,000	130,329	11,692	May 05 04:10 PM
Heery Christopher	Chief Medical Officer	Apr 24	Option Exercise	10.64	20,000	212,800	31,692	Apr 26 04:11 PM
Heery Christopher	Chief Medical Officer	Apr 24	Sale	40.00	20,000	800,068	11,692	Apr 26 04:11 PM
Heery Christopher	Chief Medical Officer	Apr 19	Option Exercise	13.16	12,345	162,503	27,334	Apr 20 04:09 PM
Heery Christopher	Chief Medical Officer	Apr 19	Sale	35.01	15,642	547,661	11,692	Apr 20 04:09 PM
Heery Christopher	Chief Medical Officer	Apr 18	Option Exercise	10.16	5,400	54,840	20,989	Apr 20 04:09 PM
Heery Christopher	Chief Medical Officer	Apr 18	Sale	35.00	6,000	210,000	14,989	Apr 20 04:09 PM
Heery Christopher	Chief Medical Officer	Apr 03	Option Exercise	15.00	3,000	45,000	18,589	Apr 04 07:35 PM
Heery Christopher	Chief Medical Officer	Apr 03	Sale	30.71	3,000	92,121	15,589	Apr 04 07:35 PM
Elghandour Rami	See Remarks	Feb 09	Sale	30.77	31,442	967,423	38,769	Feb 09 07:24 PM
Heery Christopher	Chief Medical Officer	Feb 09	Sale	30.77	6,966	214,333	15,589	Feb 09 07:26 PM
Elghandour Rami	See Remarks	Feb 07	Option Exercise	0.00	70,211	0	70,211	Feb 09 07:24 PM
Heery Christopher	Chief Medical Officer	Feb 07	Option Exercise	0.00	22,555	0	22,555	Feb 09 07:26 PM
Heery Christopher	Chief Medical Officer	Feb 03	Option Exercise	12.22	1,255	15,337	1,255	Feb 07 02:09 PM
Heery Christopher	Chief Medical Officer	Feb 03	Sale	35.11	1,255	44,068	0	Feb 07 02:09 PM
Heery Christopher	Chief Medical Officer	Jan 03	Option Exercise	15.00	2,500	37,500	2,500	Jan 05 04:46 PM
Heery Christopher	Chief Medical Officer	Jan 03	Sale	31.11	2,500	77,775	0	Jan 05 04:46 PM
SANDELL SCOTT D	10% Owner	Dec 23	Sale	31.67	390	12,353	0	Dec 27 06:48 PM
BASKETT FOREST	10% Owner	Dec 22	Sale	31.45	1,628	51,207	0	Dec 22 06:25 PM
SANDELL SCOTT D	10% Owner	Dec 21	Sale	30.74	179	5,502	0	Dec 22 06:50 PM
Makhzoumi Mohamad	10% Owner	Dec 21	Sale	30.74	179	5,502	0	Dec 22 06:47 PM
Heery Christopher	Chief Medical Officer	Dec 13	Option Exercise	11.51	12,500	143,900	12,500	Dec 14 05:16 PM
Heery Christopher	Chief Medical Officer	Dec 13	Sale	30.03	12,500	375,320	0	Dec 14 05:16 PM
New Enterprise Associates 15,	10% Owner	Jun 21	Buy	16.00	312,500	5,000,000	6,745,262	Jun 23 05:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACLX | Arcellx, Inc.

Upgrade your FINVIZ experience